↓ Skip to main content

An Enhanced Emtricitabine-Loaded Long-Acting Nanoformulation for Prevention or Treatment of HIV Infection

Overview of attention for article published in Antimicrobial Agents and Chemotherapy, December 2016

Readers on

mendeley
49 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
An Enhanced Emtricitabine-Loaded Long-Acting Nanoformulation for Prevention or Treatment of HIV Infection
Published in
Antimicrobial Agents and Chemotherapy, December 2016
DOI 10.1128/aac.01475-16
Pubmed ID
Authors
Abstract

Among various FDA approved combination antiretroviral drugs (cARVs), emtricitabine (FTC) has been a very effective nucleoside reverse transcriptase inhibitor. Thus far FTC is the only deoxycytidine nucleoside analog. However, a major drawback of FTC is its large volume distribution (averaging 1.4 L/kg) and short plasma half-life (8-10 h), necessitating a high daily dosage. Thus, we propose an innovative fabrication method of loading FTC in poly(lactic-co-glycolic acid) polymeric nanoparticles (FTC-NPs), potentially overcoming these drawbacks. Our nano-formulation demonstrated enhanced FTC loading (sized <200 nm and surface-charge of -23 mV), and no to low cytotoxicity with improved biocompatibility compared to FTC solution. An ex-vivo endosomal release assay illustrated NP entrapment prolongs FTC release over a month. Intracellular retention studies demonstrate sustained FTC retention over time with approximately 8 % (24 h) to 68 % (96 h) release with ∼0.74 ìg/10(5) cells mean retention FTC drug concentration after 4 days of study period. In vitro HIV-1 inhibition study demonstrated FTC-NPs treatment results in IC50 value ∼43 times lower in TZM-bl cells (0.00043 μg/mL) and ∼3.7 times lower (0.009 μg/mL) IC50 in PBMCs, compared to FTC solution (TZM-bl cells 0.01861 and PBMCs 0.033 μg/mL). Further on primary PBMCs, FTC-NPs also illustrates a comparable HIV-1 infection blocking efficacy to FTC solution. All the above studies substantiate that FTC nano-formulation prolongs intracellular FTC concentration and inhibition of HIV infection. Therefore, FTC-NPs potentially could be a long-acting, stable formulation to ensure once biweekly dosing to prevent or treat HIV infection.

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 49 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Unknown 49 100%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Student > Master 7 14%
Student > Ph. D. Student 6 12%
Student > Bachelor 4 8%
Student > Doctoral Student 3 6%
Researcher 3 6%
Other 4 8%
Unknown 22 45%
Readers by discipline
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 6 12%
Medicine and Dentistry 4 8%
Chemistry 4 8%
Biochemistry, Genetics and Molecular Biology 2 4%
Agricultural and Biological Sciences 2 4%
Other 7 14%
Unknown 24 49%